121.80
price down icon1.32%   -1.63
after-market 시간 외 거래: 121.46 -0.34 -0.28%
loading
전일 마감가:
$123.43
열려 있는:
$123.29
하루 거래량:
2.58M
Relative Volume:
1.76
시가총액:
$257.29B
수익:
$53.40B
순이익/손실:
$13.68B
주가수익비율:
17.69
EPS:
6.8864
순현금흐름:
$16.89B
1주 성능:
-7.33%
1개월 성능:
-1.85%
6개월 성능:
+7.36%
1년 성능:
+10.20%
1일 변동 폭
Value
$121.57
$123.92
1주일 범위
Value
$121.57
$131.68
52주 변동 폭
Value
$96.06
$133.55

노바티스 ADR Stock (NVS) Company Profile

Name
명칭
Novartis Ag Adr
Name
전화
-
Name
주소
-
Name
직원
75,883
Name
트위터
@novartis
Name
다음 수익 날짜
2025-07-17
Name
최신 SEC 제출 서류
Name
NVS's Discussions on Twitter

NVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

노바티스 ADR Stock (NVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-09-12 다운그레이드 Goldman Neutral → Sell
2025-08-08 업그레이드 Morgan Stanley Underweight → Equal-Weight
2025-02-13 다운그레이드 UBS Buy → Neutral
2025-02-12 개시 Morgan Stanley Underweight
2025-02-04 업그레이드 Deutsche Bank Hold → Buy
2024-12-04 다운그레이드 HSBC Securities Hold → Reduce
2024-09-11 다운그레이드 BofA Securities Buy → Neutral
2024-09-05 다운그레이드 Goldman Buy → Neutral
2024-09-03 다운그레이드 Jefferies Buy → Hold
2024-07-19 다운그레이드 Deutsche Bank Buy → Hold
2024-05-30 개시 Goldman Buy
2024-02-23 개시 BMO Capital Markets Market Perform
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-18 다운그레이드 HSBC Securities Buy → Hold
2023-09-25 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-07-14 개시 HSBC Securities Buy
2023-04-26 업그레이드 Deutsche Bank Hold → Buy
2023-03-27 업그레이드 Deutsche Bank Sell → Hold
2023-01-26 다운그레이드 Citigroup Buy → Neutral
2022-12-05 업그레이드 Stifel Hold → Buy
2022-09-15 다운그레이드 Credit Suisse Neutral → Underperform
2022-09-14 다운그레이드 Berenberg Buy → Hold
2022-05-09 다운그레이드 Wolfe Research Outperform → Peer Perform
2022-01-10 재개 Citigroup Buy
2021-12-14 다운그레이드 Redburn Buy → Neutral
2021-12-06 다운그레이드 Exane BNP Paribas Outperform → Neutral
2021-12-03 다운그레이드 Bryan Garnier Buy → Neutral
2021-09-20 다운그레이드 Deutsche Bank Hold → Sell
2021-03-22 개시 Bernstein Mkt Perform
2021-03-10 다운그레이드 Argus Buy → Hold
2021-02-01 다운그레이드 Cowen Outperform → Market Perform
2021-01-15 개시 Deutsche Bank Buy
2020-09-29 개시 Berenberg Buy
2020-09-10 업그레이드 UBS Neutral → Buy
2020-09-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-15 업그레이드 Citigroup Neutral → Buy
2020-03-10 업그레이드 Morgan Stanley Underweight → Equal-Weight
2020-02-25 다운그레이드 Guggenheim Buy → Neutral
2019-04-25 업그레이드 Guggenheim Neutral → Buy
2019-04-25 업그레이드 Liberum Hold → Buy
2019-04-10 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2019-01-02 다운그레이드 JP Morgan Neutral → Underweight
2018-12-11 재개 Jefferies Buy
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Underperform → Buy
2018-05-29 다운그레이드 HSBC Securities Buy → Hold
2018-05-25 업그레이드 Credit Suisse Underperform → Neutral
2018-01-25 재확인 Leerink Partners Outperform
2017-12-06 다운그레이드 BofA/Merrill Neutral → Underperform
2017-07-26 업그레이드 Morgan Stanley Underweight → Overweight
2017-07-05 다운그레이드 Credit Suisse Neutral → Underperform
2017-03-09 개시 Liberum Buy
모두보기

노바티스 ADR 주식(NVS)의 최신 뉴스

pulisher
11:00 AM

Pharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population - GlobeNewswire Inc.

11:00 AM
pulisher
07:20 AM

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

07:20 AM
pulisher
Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025
pulisher
Oct 28, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com Nigeria

Oct 28, 2025
pulisher
Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025
pulisher
Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025
pulisher
Oct 22, 2025

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Oct 22, 2025
pulisher
Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Oct 22, 2025
pulisher
Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025
pulisher
Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025
pulisher
Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025
pulisher
Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025
pulisher
Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm

Oct 15, 2025
pulisher
Oct 14, 2025

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm

Oct 14, 2025
pulisher
Oct 13, 2025

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail

Oct 13, 2025
pulisher
Oct 11, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025
pulisher
Oct 08, 2025

Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 08, 2025
pulisher
Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025
pulisher
Oct 03, 2025

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha

Oct 03, 2025
pulisher
Sep 30, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva

Sep 30, 2025
pulisher
Sep 29, 2025

Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm

Sep 29, 2025
pulisher
Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis

Sep 29, 2025
pulisher
Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025
pulisher
Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm

Sep 25, 2025
pulisher
Sep 24, 2025

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm

Sep 24, 2025
pulisher
Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025
pulisher
Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025
pulisher
Sep 13, 2025

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail

Sep 13, 2025
pulisher
Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

노바티스 ADR (NVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
$291.77
price down icon 0.11%
$118.50
price up icon 0.53%
drug_manufacturers_general PFE
$24.29
price down icon 0.86%
자본화:     |  볼륨(24시간):